We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

FUJIREBIO

  Gold Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Fujirebio Europe Launches RoboBlot Instrument for Fully Automated Processing of INNO-LIA Score Assays

By LabMedica International staff writers
Posted on 19 Jan 2022
Print article
Image: RoboBlot (Photo courtesy of Fujirebio)
Image: RoboBlot (Photo courtesy of Fujirebio)

Fujirebio Europe (Gent, Belgium) has announced today the commercial launch of the RoboBlot instrument, a closed system for the automated processing of the widely used INNO-LIA Score assays.

The system’s pre-programmed test protocols provide start-to-finish automation of strip-based INNO-LIA Score assays, from sample addition, over strip processing, image capture, to result interpretation and where applicable laboratory information system (LIS) communication.

RoboBlot extends the range of automated solutions already offered by Fujirebio Europe for the INNO-LIA Score assay portfolio. It offers high-throughput testing, full automation with pipetting up to 50 samples and integrated camera for scanning and interpretation with Fujirebio LiRAS software, providing complete traceability with minimal hands-on time. It offers a customized fit with individual laboratory needs. Other automated solution for this portfolio is the TENDIGO.

“High throughput testing and more automation are an increasingly pressing need for laboratories. The typical drawbacks of manual testing, such as long hands-on time, inconsistent assay handling and issues with traceability, will become part of the past,” said Christiaan De Wilde, CEO at Fujirebio Europe. “The RoboBlot instrument will radically improve the laboratory workflow for our customers, from tedious manual or semi-automated work into fully automated testing.”

Related Links:
Fujirebio Europe 

Gold Supplier
Saliva Collection Kit
SpeciMAX Stabilized Saliva Collection Kit
New
Microplate Washer
STAT FAX 2600
New
Gold Supplier
Immunofluorescence Incubator
RaFIA Immunofluorescence Incubator
New
Microplate Incubator and Shaker
EZ ThermoShake

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Hematology

view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more

Industry

view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.